Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models.
用户sToGMn7iJdc8
19天前
43
10
已关闭
DOI:
文献链接:
其他信息:
Y Sato, S Tsuchida, Y Mizukoshi, H Inaba, S Kato…
2025
jnm.snmjournals.org
… feasibility of PD-29875 for … that PD-29875 was internalized in BxPC3-CLDN18.2 cells but not BxPC3 cells. In in vivo biodistribution experiments, 64 Cu-PD-29875 and 177 Lu-PD-29875 …
